Minhai COVID-19 vaccine
Minhai COVID-19 vaccine (Chinese: 康泰民海新冠疫苗), trademarked as KCONVAC (Chinese: 可维克; pinyin: Kěwéikè), is a COVID-19 vaccine developed by Shenzhen Kangtai Biological Products Co. Ltd and its subsidiary, Beijing Minhai Biotechnology Co., Ltd.
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Inactivated |
Clinical data | |
Other names | KCONVAC (Chinese: 可维克; pinyin: Kěwéikè) |
Routes of administration | Intramuscular |
Legal status | |
Legal status |
Part of a series on the |
COVID-19 pandemic |
---|
![]() Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom. |
|
Medical response |
|
![]() |
Clinical trials
In October 2020, KCONVAC started phase I clinical trials with 180 participants in China.[1] Later, KCONVAC started phase II trials with 1,000 participants in China.[2]
In May 2021, KCONVAC started phase III trials for global trials with 28,000 participants.[3]
Authorizations
Full authorization
Emergency authorization
Allowed for travel |
On 14 May 2021, the vaccine became the fourth inactivated Chinese Vaccine to be authorised for emergency use.[6]
References
- Clinical trial number NCT04756323 for "A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19) " at ClinicalTrials.gov
- Clinical trial number NCT04758273 for "A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)" at ClinicalTrials.gov
- Clinical trial number NCT04852705 for "A Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Adults Aged 18 Years and Older (COVID-19)" at ClinicalTrials.gov
- Clinical trial number NCT05003479 for "A Phase I Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years (COVID-19)" at ClinicalTrials.gov
- Clinical trial number NCT05003466 for "A Phase II Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years (COVID-19)" at ClinicalTrials.gov
- Reuters Staff (14 May 2021). "Kangtai Biological's COVID-19 vaccine gets emergency use approval in China". Reuters. Retrieved 20 May 2021.
{{cite news}}
:|author=
has generic name (help)
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.